# OnCo record classic (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/classic/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "classic", "NCT00411229" ;
  schema:name "CLASSIC"@en ;
  schema:alternateName "CLASSIC trial"@en, "L_9570"@en ;
  schema:description "CLASSIC showed that six months of capecitabine and oxaliplatin after a thorough stomach cancer operation stops the cancer returning in many more people, with 68 percent free of disease at five years against 53 percent with surgery alone, and more of them alive; it made CAPOX one of the two standard adjuvant treatments in East Asia."@en ;
  schema:url <https://onco.cc/trials/classic/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00411229> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/gastric/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/oxaliplatin/> ;
  onco:companies <https://onco.cc/companies/sanofi/>, <https://onco.cc/companies/roche-genentech/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-classic-adjuvant-capox-gastric-bang-lancet-2012/>, <https://onco.cc/key-papers/paper-classic-5-year-follow-up-noh-lancet-oncol-2014/> .